SunTrust Banks assumed coverage on shares of Translate Bio (NASDAQ:TBIO) in a research report report published on Friday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $40.00 target price on the stock.

A number of other brokerages also recently commented on TBIO. Jefferies Financial Group upped their target price on Translate Bio from $17.00 to $29.00 and gave the stock a buy rating in a research note on Tuesday, June 23rd. Roth Capital upped their price objective on Translate Bio from $25.00 to $30.00 and gave the stock a buy rating in a research report on Tuesday, June 23rd. ValuEngine cut shares of Translate Bio from a buy rating to a hold rating in a research note on Monday, June 1st. Zacks Investment Research upgraded shares of Translate Bio from a hold rating to a buy rating and set a $18.00 target price for the company in a research note on Friday, June 19th. Finally, TheStreet upgraded shares of Translate Bio from a d rating to a c- rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Translate Bio has a consensus rating of Buy and an average price target of $29.00.

TBIO opened at $18.80 on Friday. The firm has a 50 day moving average of $17.76 and a two-hundred day moving average of $11.21. The firm has a market capitalization of $1.23 billion, a PE ratio of -11.06 and a beta of 0.53. The company has a current ratio of 4.12, a quick ratio of 4.12 and a debt-to-equity ratio of 0.08. Translate Bio has a 12-month low of $6.80 and a 12-month high of $28.09.

Translate Bio (NASDAQ:TBIO) last posted its earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.20. The company had revenue of $4.65 million during the quarter, compared to the consensus estimate of $2.23 million. Translate Bio had a negative net margin of 859.22% and a negative return on equity of 63.61%. As a group, analysts predict that Translate Bio will post -1.57 EPS for the current fiscal year.

In related news, major shareholder Human Genetic Therapies Shire sold 40,086 shares of Translate Bio stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $19.75, for a total value of $791,698.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 12.30% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aperio Group LLC purchased a new position in Translate Bio in the 1st quarter valued at about $101,000. BlackRock Inc. raised its holdings in shares of Translate Bio by 1.1% during the first quarter. BlackRock Inc. now owns 3,193,058 shares of the company’s stock valued at $31,836,000 after acquiring an additional 34,487 shares during the last quarter. First Allied Advisory Services Inc. lifted its position in shares of Translate Bio by 46.2% in the fourth quarter. First Allied Advisory Services Inc. now owns 19,000 shares of the company’s stock valued at $155,000 after acquiring an additional 6,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Translate Bio by 7.4% in the fourth quarter. Geode Capital Management LLC now owns 546,581 shares of the company’s stock worth $4,449,000 after acquiring an additional 37,577 shares during the last quarter. Finally, Camber Capital Management LP increased its position in shares of Translate Bio by 17.7% during the first quarter. Camber Capital Management LP now owns 1,765,000 shares of the company’s stock worth $17,597,000 after purchasing an additional 265,000 shares in the last quarter. Hedge funds and other institutional investors own 83.92% of the company’s stock.

Translate Bio Company Profile

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Recommended Story: Why do commodities matter?

Analyst Recommendations for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.